BACKGROUND: Decompressive surgery for malignant middle cerebral artery infarction increases the number of surviving patients; this, however, leaves some patients severely disabled. This study analyzed the patients' retrospective consent to hemicraniectomy in light of the experienced functional outcome 12 months after hospital stay. METHODS: This retrospective study included all patients who underwent decompressive hemicraniectomy for malignant middle cerebral artery infarction in the Department of Neurology, University of Erlangen, Germany, from January 2006 until March 2009. Data on mortality and functional outcome (measured by the modified Rankin Scale; mRS) 6 and 12 months after treatment were correlated with retrospective consent to hemicraniectomy as well as with a quality of life instrument (EuroQol). Data were obtained by structured telephone interviews with the patients themselves or their closest relatives. RESULTS: In the study period 28 patients received decompressive surgery. Retrospective consent to hemicraniectomy was 82.1%. Five patients, or their closest relatives, would not agree to hemicraniectomy again, given their functional outcome after 1 year. Two out of two patients who experienced an mRS of 5 would not have consented. Low quality of life was most often declared in this subgroup. CONCLUSIONS: Retrospective consent to hemicraniectomy for treatment of malignant MCA infarction depends on functional long-term outcome. We need to identify those patients who would survive the malignant MCA infarction due to decompressive surgery but only reach a severely reduced functional status.
BACKGROUND: Decompressive surgery for malignant middle cerebral artery infarction increases the number of surviving patients; this, however, leaves some patients severely disabled. This study analyzed the patients' retrospective consent to hemicraniectomy in light of the experienced functional outcome 12 months after hospital stay. METHODS: This retrospective study included all patients who underwent decompressive hemicraniectomy for malignant middle cerebral artery infarction in the Department of Neurology, University of Erlangen, Germany, from January 2006 until March 2009. Data on mortality and functional outcome (measured by the modified Rankin Scale; mRS) 6 and 12 months after treatment were correlated with retrospective consent to hemicraniectomy as well as with a quality of life instrument (EuroQol). Data were obtained by structured telephone interviews with the patients themselves or their closest relatives. RESULTS: In the study period 28 patients received decompressive surgery. Retrospective consent to hemicraniectomy was 82.1%. Five patients, or their closest relatives, would not agree to hemicraniectomy again, given their functional outcome after 1 year. Two out of two patients who experienced an mRS of 5 would not have consented. Low quality of life was most often declared in this subgroup. CONCLUSIONS: Retrospective consent to hemicraniectomy for treatment of malignant MCA infarction depends on functional long-term outcome. We need to identify those patients who would survive the malignant MCA infarction due to decompressive surgery but only reach a severely reduced functional status.
Authors: Patrick Mitchell; Barbara A Gregson; John Crossman; Chris Gerber; Alastair Jenkins; Claire Nicholson; Nick V Todd; Nick Ross; Parameswaran Bhattathiri; Justin Nissen; Peter J Crawford; Guy Wynne-Jones; Robin P Sengupta; Laura Graham; Akif Gani; Michelle Davis; Chris Gray; David Barer; Paul Dorman; David Millar; Julia Williamson; Holly Durham; Alison Jones; Helen Hastie; A David Mendelow Journal: Lancet Neurol Date: 2009-07 Impact factor: 44.182
Authors: Jeannette Hofmeijer; L Jaap Kappelle; Ale Algra; G Johan Amelink; Jan van Gijn; H Bart van der Worp Journal: Lancet Neurol Date: 2009-03-05 Impact factor: 44.182
Authors: Eric Jüttler; Stefan Schwab; Peter Schmiedek; Andreas Unterberg; Michael Hennerici; Johannes Woitzik; Steffen Witte; Ekkehart Jenetzky; Werner Hacke Journal: Stroke Date: 2007-08-09 Impact factor: 7.914
Authors: Lisa Sweet; Dimitrios Adamis; David J Meagher; Daniel Davis; David C Currow; Shirley H Bush; Christopher Barnes; Michael Hartwick; Meera Agar; Jessica Simon; William Breitbart; Neil MacDonald; Peter G Lawlor Journal: J Pain Symptom Manage Date: 2013-12-31 Impact factor: 3.612
Authors: Michel T Torbey; Julian Bösel; Denise H Rhoney; Fred Rincon; Dimitre Staykov; Arun P Amar; Panayiotis N Varelas; Eric Jüttler; DaiWai Olson; Hagen B Huttner; Klaus Zweckberger; Kevin N Sheth; Christian Dohmen; Ansgar M Brambrink; Stephan A Mayer; Osama O Zaidat; Werner Hacke; Stefan Schwab Journal: Neurocrit Care Date: 2015-02 Impact factor: 3.210
Authors: Hermann Neugebauer; Claire J Creutzfeldt; J Claude Hemphill; Peter U Heuschmann; Eric Jüttler Journal: Neurocrit Care Date: 2014-08 Impact factor: 3.210
Authors: Adnan I Qureshi; Saqib A Chaudhry; Bo Connelly; Emily Abott; Tariq Janjua; Stanley H Kim; Jefferson T Miley; Gustavo J Rodriguez; Guven Uzun; Masaki Watanabe Journal: Crit Care Med Date: 2013-06 Impact factor: 7.598